The MCD group showed reduced FAS, ACC1, CPT1α, AOX, LFABP, ApoB, and MTTP expression, confirming a successfully developed NAFLD model. The gene discussed is CPT1A; the disease is metabolic dysfunction-associated steatotic liver disease.